Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors

PVRI Member Authors: Luke Howard, Martin Wilkins


The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied consecutive incident PAH patients (n = 146) between January 1, 2008, and July 15, 2011. Patients were divided into two groups: the PAH–No CV group included patients with no CV risk factors (obesity, systemic hypertension, type 2 diabetes mellitus, permanent atrial fibrillation, mitral and/or aortic valve disease, and coronary artery disease), and the PAH-CV group included patients with at least one. The response to PAH treatment was analyzed in all the patients who received PAH drug therapy. The PAH–No CV group included 43 patients, and the PAH-CV group included 69 patients. Patients in the PAH–No CV group were younger than those in the PAH-CV group (P < 0.0001). In the PAH–No CV group, 16 patients (37%) improved on treatment and 27 (63%) did not improve, compared with 11 (16%) and 58 (84%) in the PAH-CV group, respectively (P = 0.027 after adjustment for age). There was no difference in survival at 30 months (P = 0.218). In conclusion, in addition to older age, CV risk factors may predict a reduced response to PAH drug therapy in patients with PAH.

Read the full article online


Heart Arrest/ Block/ Defects/ Diseases/ Failure/ Rate/ Infarction
Pulmonary Arterial Hypertension
Pulmonary Hypertension


Athanasios Charalampopoulos, Luke S. Howard, Ioanna Tzoulaki, Wendy Gin-Sing, Julia Grapsa, Martin R. Wilkins, Rachel J. Davies, Petros Nihoyannopoulos, Susan B. Connolly, and J. Simon R. Gibbs

Published in:

Pulmonary Circulation Vol 4: No 4 cover image

December 2014

Pulmonary Circulation Vol 4: No 4

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI